 |
Indication & Dosage |
| |
| |
| Intramuscular |
| ENDOMETRIOSIS AND UTERINE FIBROIDS |
| Adult:
3 or 3.75 mg by IM Inj every 4 wk for up to 6 mth. Begin treatment during the 1st 5 days of the menstrual cycle. |
| |
| Parenteral |
| PROSTATIC CANCER |
| Adult:
In conjunction with gonadotrophins, 0.1 mg daily by SC Inj starting from the 2nd day of the menstrual cycle for 10-12 days. |
| |
| Parenteral |
| PRECOCIOUS PUBERTY |
| Adult:
In conjunction with gonadotrophins, 0.1 mg daily by SC Inj starting from the 2nd day of the menstrual cycle for 10-12 days. |
| |
| Subcutaneous |
| FEMALE INFERTILITY |
| Child:
In conjunction with gonadotrophins, 0.1 mg daily by SC Inj starting from the 2nd day of the menstrual cycle for 10-12 days. |
|
| |
|
| Precautions |
Patients with pituitary adenoma; weight-related amenorrhoea until weight corrected; polycystic ovary disease or endometriotic cysts; metabolic bone disease. Monitor closely as there may be initial worsening of signs and symptoms during first few wk of therapy. Contraceptive measures to be taken to protect against unwanted ovulation in females. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Hot flushes, weight gain, sleep disturbances, headache, hypertension, weight gain, decreased libido, abnormal vision, mood disorders, nausea, abdominal pain or discomfort, rash and impotence. Transient pain, redness or local inflammation at the inj site may occur. Prostate cancer: During first few wk, bone pain, worsening of urinary obstruction symptoms and/or worsening of neurological signs of vertebral metastases (back pain, weakness or paresthesia of the lower limbs). Gynaecomastia, vertigo and dizziness. Endometriosis: Initial worsening of pelvic pain, dysmenorrhoea with heavy menstrual bleeding or spotting. Sweating, vaginal dryness, dyspareunia, breast pain, hair loss, small loss in bone density. Precocious puberty: Mild or moderate withdrawal bleeding in the first mth of treatment. |
| |
|
| Adverse Drug Reactions |
Anaphylactic shock. |
| |
|
| Interactions |
Decrease in LHRH receptors in pituitary with hyperprolactinaemic drugs antagonises effects of triptorelin. |
| |
|
|
|
